GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (FRA:N4CN) » Definitions » Cyclically Adjusted PB Ratio

Paratek Pharmaceuticals (FRA:N4CN) Cyclically Adjusted PB Ratio : 0.36 (As of Jun. 10, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Paratek Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-06-10), Paratek Pharmaceuticals's current share price is €2.024. Paratek Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 was €5.59. Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.36.

The historical rank and industry rank for Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:N4CN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.11   Med: 0.28   Max: 0.65
Current: 0.36

During the past years, Paratek Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 0.65. The lowest was 0.11. And the median was 0.28.

FRA:N4CN's Cyclically Adjusted PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 1.67 vs FRA:N4CN: 0.36

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Paratek Pharmaceuticals's adjusted book value per share data for the three months ended in Jun. 2023 was €-3.245. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €5.59 for the trailing ten years ended in Jun. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Paratek Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Paratek Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.17 0.28 0.28 0.19

Paratek Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.25 0.19 0.33 0.31

Competitive Comparison of Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Paratek Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.024/5.59
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paratek Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, Paratek Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2023 was:

Adj_Book=Book Value per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-3.245/128.7287*128.7287
=-3.245

Current CPI (Jun. 2023) = 128.7287.

Paratek Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201309 36.424 98.790 47.462
201312 33.354 98.326 43.667
201403 32.052 99.695 41.387
201406 19.299 100.560 24.705
201409 16.627 100.428 21.313
201412 5.356 99.070 6.959
201503 5.417 99.621 7.000
201506 7.153 100.684 9.145
201509 6.083 100.392 7.800
201512 5.278 99.792 6.808
201603 3.719 100.470 4.765
201606 4.187 101.688 5.300
201609 3.366 101.861 4.254
201612 2.906 101.863 3.672
201703 3.080 102.862 3.855
201706 3.656 103.349 4.554
201709 3.004 104.136 3.713
201712 2.494 104.011 3.087
201803 2.857 105.290 3.493
201806 2.307 106.317 2.793
201809 1.554 106.507 1.878
201812 1.296 105.998 1.574
201903 0.438 107.251 0.526
201906 -0.372 108.070 -0.443
201909 -1.121 108.329 -1.332
201912 -0.896 108.420 -1.064
202003 -1.180 108.902 -1.395
202006 -1.244 108.767 -1.472
202009 -1.486 109.815 -1.742
202012 -1.807 109.897 -2.117
202103 -2.131 111.754 -2.455
202106 -1.717 114.631 -1.928
202109 -1.784 115.734 -1.984
202112 -2.187 117.630 -2.393
202203 -2.403 121.301 -2.550
202206 -2.579 125.017 -2.656
202209 -3.027 125.227 -3.112
202212 -2.850 125.222 -2.930
202303 -3.082 127.348 -3.115
202306 -3.245 128.729 -3.245

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Paratek Pharmaceuticals  (FRA:N4CN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Paratek Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Paratek Pharmaceuticals (FRA:N4CN) Business Description

Traded in Other Exchanges
N/A
Address
75 Park Plaza, 4th Floor, Boston, MA, USA, 02116
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Paratek Pharmaceuticals (FRA:N4CN) Headlines

No Headlines